Genetic and Developmental Disorders
9 cases on spinal muscular atrophy therapy selection, neurofibromatosis, tuberous sclerosis, mitochondrial disease, Pompe disease, cerebral ALD, and Rett syndrome pharmacotherapy — choose a case below to open its full multi-voice debate.
A five-month-old girl newly diagnosed with spinal muscular atrophy needs a disease-modifying therapy started before more motor neurons are lost. All three approved agents work — the disagreement is which one, and no trial has ever put them head-to-head.
A newborn screens positive for SMA with three copies of SMN2 — a genotype whose natural history genuinely ranges from wheelchair-dependent to lifelong ambulatory. Treat every screen-positive infant immediately, or does three-copy SMA earn a different conversation?
A toddler on nusinersen since infancy has plateaued and is now losing function. Switch to risdiplam, add gene therapy on top of an SMN2 splicing modifier, or hold the current course longer — real practice with only limited safety and efficacy data behind any of the three.
A 13-year-old with NF1 has a painful, growing plexiform neurofibroma right as puberty accelerates its growth. Selumetinib shrinks these tumors, but stopping it usually lets them regrow — meaning today's decision is really about starting a drug she may take for the rest of her adolescence.
A boy with tuberous sclerosis has a growing SEGA, refractory seizures, and a renal angiomyolipoma — all three genuinely responsive to the same drug, everolimus, but each with its own trial, its own target level, and its own monitoring plan. When they disagree on how aggressively to dose, whose threshold wins?
A boy with genetically confirmed MELAS is offered the standard mitochondrial 'cocktail' of CoQ10, carnitine, and riboflavin. The mechanism sounds plausible and the risk looks low — but no placebo-controlled trial has ever shown the combination changes outcomes, and a targeted single agent might.
A newborn screens positive for infantile Pompe disease with early signs of cardiac involvement. Starting enzyme replacement immediately protects a heart that can't wait — but starting it before his CRIM status is known could doom the treatment entirely if he turns out CRIM-negative.
A boy with X-linked adrenoleukodystrophy has early MRI changes but no symptoms at all. Both gene therapy and transplant only work before real neurologic damage sets in — but most boys with early lesions like his never progress to cerebral disease. Treat the MRI, or watch the boy?
A girl with Rett syndrome is offered trofinetide, the first drug ever approved for the condition's core features. The trial's effect size was modest and its most common side effect is diarrhea — a real problem in a girl whose nutrition and growth are already precarious.